- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001566
A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas
This is a single arm study.
The tumor specimen is analyzed for the presence of a fusion protein which corresponds to available peptides. Patients undergo T cell harvest 10 days after an initial priming peptide-pulsed antigen presenting cell (APC) vaccine is performed.
Fresh APCs are utilized for initial priming vaccination. All subsequent vaccinations will use cryopreserved APCs. Minimum number of APCs administered per vaccination is 100,000/kg and maximum is 100,000,000/kg.
Patients undergo cytoreductive therapy for the treatment of their particular malignancy. This therapy usually consists of multiagent chemotherapy in the context of a separate protocol.
Following chemotherapy, infusion of harvested T cells followed by infusion of peptide-pulsed APC vaccinations occurs every 6 weeks for a total of 3 post-priming vaccinations. Influenza vaccine is administered by intramuscular injection concurrent to peptide-pulsed APC vaccines.
Interleukin -2 (IL-2) is administered as a continuous intravenous (IV) infusion for 4 days/week for 3 successive weeks starting on the same day as T cell /peptide-pulsed infusions.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
Patients with fusion protein bearing, metastatic malignancies of the following histologic subtypes are eligible for evaluation for treatment on this protocol: alveolar rhabdomyosarcoma (AR), and Ewing's sarcoma family of tumors (ESFT) which includes classical, atypical and extraosseous Ewing's sarcoma, peripheral primitive neuroectodermal tumors, peripheral neuroepithelioma, primitive sarcoma of bone, and ectomesenchymoma. Eligibility will not be confirmed until the presence of a tumor-specific fusion protein is documented by reverse transcription polymerase chain reaction (RT-PCR) which corresponds to one of the tumor-specific peptides available for vaccination.
Patients with Stage IV or metastatic disease are eligible to be enrolled on study at the time of initial presentation with tumor, prior to any cytoreductive therapy.
Alternatively, patients who have recurrent disease, but who have been remotely treated (completed all antineoplastic therapy greater than or equal to one year prior to enrollment for patients who are greater than 5 years of age, or completed all antineoplastic therapy greater than 6 months prior to enrollment for patients who are less than or equal to 5 years of age), are also eligible for enrollment prior to any subsequent cytoreductive therapy.
Patients who have received cytoreductive therapy for Stage IV or metastatic disease may be enrolled at the time of completion of cytoreductive therapy if an apheresis specimen is available which was collected and processed prior to cytotoxic therapy according to the guidelines described in the protocol Section 3.2.2.
Such products will have been obtained by apheresis at the Clinical Center, National Institutes of Health (NIH), with informed consent administered as per protocol 98-C-37, 97-C-0050 or as described on standard government request form 2626 for invasive procedures.
Patients must be less than or equal to 35 years at the time of initial diagnosis of alveolar rhabdomyosarcoma or ESFT, weight greater than 10 kg at the time of apheresis. Patients between 10-15 kg must be approved by the apheresis unit in the Department of Transfusion Medicine (DTM) prior to enrollment on the protocol.
All patients or their legal guardians must give written informed consent indicating their understanding of the investigational nature and risks of the study.
Patients must have adequate renal function (serum creatinine (Cr) less than 1.5 mg/dl or creatinine clearance (Cr Cl), greater than 60 ml/min./1.73 m^2 and liver function (transaminases less than 3 times normal, bilirubin less than 2.0 mg/dl). Patients will not be excluded based upon abnormal hepatic function which is related to hepatic involvement by tumor.
For remotely treated patients, a CD4 count of greater than or equal to 400 cells/mm^3 is required.
EXCLUSION CRITERIA:
Women who are pregnant or lactating.
Patients with human immunodeficiency virus infection due to confounding effects on immune function.
Patients with hepatitis B or hepatitis C infection will be excluded due to the untoward risks to personnel working with blood specimens.
Patients who require daily oral corticosteroid therapy for any underlying disease will be excluded.
Topical or inhaled corticosteroids are permitted.
Patients who are allergic to eggs, egg products, or thimerosal, or have a history of Guillain-Barre syndrome may be enrolled on study but are ineligible to receive the influenza vaccine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Peptide vaccine/autologous T cell transplant/indinavir therapy
Patients receive oral indinavir sulfate 350 mg/m^2 administered every 8 hours; maximum dose i.e. 800 mg every 8 hours; peptide pulsed dendritic cells 1 x 10^6 injection; harvested autologous T cells (minimum dose 1 x 10^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
|
3 syringes containing 1 x 10^6peptide pulsed dendritic cells
Oral dose, 350 mg/m^2 administered every 8 hours.
Maximum dose is 800 mg every 8 hours.
Other Names:
Harvested autologous T cells, minimum dose 1 x 10^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With an Immune Response to Tumor-specific and Non-tumor Specific Peptides During a Period of Immune Reconstitution
Time Frame: 20 weeks post vaccination
|
Immune response was defined as a percent specific lysis of >10% following challenge with peptide pulsed targets, or interferon gamma production following challenge with peptide pulsed targets >2-fold that found with no-peptide controls or a proliferation index >3.0.
Tumor specific peptides: Ewings sarcoma Type 1: EF-1 (EWS/FLI-1)*SSSYGQQN/PSYDSVRRGA,Ewing's Sarcoma Type 2: EF-2 (EWS/FLI-2)* SSSYGQ/QSSLLAYNT, Alveolar rhabdomyosarcoma: PXFK (PAX3/FKHR)† TIGNGLSPQ/NSIRHNLSL. Non-tumor specific peptide:HPV16E7 MLDLQPETT-MET-9-THR. See protocol link module for additional information re: peptides.
|
20 weeks post vaccination
|
The Percent of Patients Who Recover CD4 Counts Within 6 Months of Completion of Chemotherapy
Time Frame: 2 to 6 months
|
CD4 counts were measured from peripheral blood using standard flow cytometric techniques at the following timepoints: 2 months post-chemotherapy, 4 months post-chemotherapy and 6 months post-chemotherapy.
To be eligible for evaluation for this endpoint, patient much have been <10 years of age and sustained a CD4 count of <300 cells/mcl upon completion of standard therapy.
Recovery was defined as a CD4 count > 500 cells/mcl at any timepoint within 6 months of completing chemotherapy.
|
2 to 6 months
|
Number of Participants With an Immune Response to the Translocation Breakpoint Peptide
Time Frame: 5 years
|
Immune responses were measured following 3 sequential influenza vaccines during the same period as the peptide-pulsed dendritic cell vaccines.
|
5 years
|
Number of Participants With an Immune Response to Non-Tumor-specific Peptide E7
Time Frame: 5 years
|
Immune response was defined as a percent specific lysis of >10% following challenge with peptide pulsed targets, or interferon gamma production following challenge with peptide pulsed targets >2-fold that found with no-peptide controls or a proliferation index >3.0.
|
5 years
|
Number of Participants With an Immune Response to Tumor-Specific Peptides at the Time of Presentation
Time Frame: Once per enrollment
|
Immune response was defined as a percent specific lysis of >10% following challenge with tumor peptide pulsed targets, or interferon gamma production following challenge with tumor peptide pulsed targets >2-fold that found with no-peptide controls or a proliferation index >3.0 to tumor peptide targets.Tumor specific peptides: Ewings sarcoma Type 1: EF-1 (EWS/FLI-1)*SSSYGQQN/PSYDSVRRGA,Ewing's Sarcoma Type 2: EF-2 (EWS/FLI-2)* SSSYGQ/QSSLLAYNT, Alveolar rhabdomyosarcoma: PXFK (PAX3/FKHR)† TIGNGLSPQ/NSIRHNLSL. See protocol link module for additional information re: peptides.
|
Once per enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events
Time Frame: 5 years
|
Here are the number of participants with adverse events.
For the detailed list of adverse events see the adverse event module.
|
5 years
|
Percentage of Participants Overall Survival
Time Frame: 5 years
|
Overall survival is defined as the time between the first day of treatment to the day of death.
|
5 years
|
Percent of Participants: Event Free Survival
Time Frame: 5 years
|
Event free survival is calculated from the date of diagnosis for patients enrolled with newly diagnosed metastatic disease and from the date of the last recurrence detection before enrollment on this study for patients with recurrent disease.
|
5 years
|
Median Overall Survival
Time Frame: 5.4 years
|
Overall survival is defined as the time between the first day of treatment to the day of death.
|
5.4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Crystal Mackall, M.D., National Cancer Institute, National Institutes of Health
Publications and helpful links
General Publications
- Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, Berzofsky JA. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res. 1993 Jul 15;53(14):3257-61.
- Mackall CL, Bare CV, Granger LA, Sharrow SO, Titus JA, Gress RE. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol. 1996 Jun 15;156(12):4609-16.
- Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, Horowitz ME, Magrath IT, Shad AT, Steinberg SM, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995 Jan 19;332(3):143-9. doi: 10.1056/NEJM199501193320303.
- Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC, Berzofsky JA, Carter CS, Read EJ, Helman LJ, Mackall CL. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med. 2005 Nov;11(11):1238-43. doi: 10.1038/nm1312. Epub 2005 Oct 16.
- Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008 Aug 1;14(15):4850-8. doi: 10.1158/1078-0432.CCR-07-4065.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Osteosarcoma
- Neoplasms, Bone Tissue
- Neoplasms, Connective Tissue
- Neoplasms, Muscle Tissue
- Myosarcoma
- Sarcoma
- Sarcoma, Ewing
- Rhabdomyosarcoma
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Indinavir
Other Study ID Numbers
- 970052
- 97-C-0052
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rhabdomyosarcoma
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingAlveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma | Metastatic Embryonal Rhabdomyosarcoma | Metastatic Rhabdomyosarcoma | Solid Alveolar RhabdomyosarcomaUnited States, Canada, Australia, Puerto Rico, Saudi Arabia
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Previously Untreated Childhood RhabdomyosarcomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Embryonal-botryoid Childhood RhabdomyosarcomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Adult Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Metastatic Childhood Soft Tissue Sarcoma | Childhood Alveolar Rhabdomyosarcoma | Childhood Embryonal Rhabdomyosarcoma | Untreated Childhood RhabdomyosarcomaUnited States, Canada, Australia, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood RhabdomyosarcomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingRhabdomyosarcoma | Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Sclerosing Rhabdomyosarcoma | Spindle Cell RhabdomyosarcomaUnited States, Canada, Puerto Rico, Australia, New Zealand
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Previously Treated Childhood Rhabdomyosarcoma | Adult Rhabdomyosarcoma | Childhood Alveolar Rhabdomyosarcoma | Childhood Pleomorphic Rhabdomyosarcoma | Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar FeaturesUnited States, Canada, Australia, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingEmbryonal Rhabdomyosarcoma | Fusion-Negative Alveolar Rhabdomyosarcoma | Spindle Cell/Sclerosing RhabdomyosarcomaUnited States, Australia, Canada, New Zealand
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAdult Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Embryonal-botryoid Childhood Rhabdomyosarcoma | Previously Untreated Childhood RhabdomyosarcomaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Previously Untreated Childhood RhabdomyosarcomaUnited States
Clinical Trials on therapeutic autologous dendritic cells
-
Jonsson Comprehensive Cancer CenterKite, A Gilead CompanyCompletedClear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Institutes of Health (NIH)CompletedBrain and Central Nervous System TumorsUnited States
-
Jonsson Comprehensive Cancer CenterCompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)Terminated
-
Lisata Therapeutics, Inc.CompletedMelanoma (Skin)United States
-
Institut Paoli-CalmettesCompleted
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)UnknownMelanoma (Skin)United States
-
Gary Archer Ph.D.National Cancer Institute (NCI)CompletedMalignant Neoplasms of BrainUnited States
-
Dartmouth-Hitchcock Medical CenterNational Cancer Institute (NCI)CompletedMelanoma (Skin)United States
-
Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum...Unknown